Safety of Antibacterial and Antiprotozoal Medicinal Products
https://doi.org/10.30895/2312-7821-2022-10-2-196-199
Abstract
The experts of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recalls of antibacterial and antiprotozoal medicinal products and/or the need for labelling updates due to changes in the safety profile. The analysis revealed 16 decisions containing information on the following medicines registered in Russia: ertapenem, сeftriaxone, cefazolin, аmoxicillin, сefoperazone+sulbactam, piperacillin+tazobactam, сlindamycin, teicoplanin, rifampin, co-trimoxazole, hydroxychloroquine.
About the Authors
E. V. Shubnikova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Elena V. Shubnikova, Cand. Sci. (Med.)
8/2 Petrovsky Blvd, Moscow 127051
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Tatyana M. Bukatina, Cand. Sci (Med.)
8/2 Petrovsky Blvd, Moscow 127051
A. A. Druzhinina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Anna A. Druzhinina.
8/2 Petrovsky Blvd, Moscow 127051
E. O. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Evgeniya O. Zhuravleva.
8/2 Petrovsky Blvd, Moscow 127051
G. V. Kutekhova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Galina V. Kutekhova.
8/2 Petrovsky Blvd, Moscow 127051
N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Nataliya Yu. Velts, Cand. Sci. (Biol.), Associate Professor.
8/2 Petrovsky Blvd, Moscow 127051
References
1. Bush K, Bradford PA. β-lactams and β-lactamase inhibi tors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247. https://doi.org/10.1101/cshperspect.a025247
2. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003;330(5):1005–14. https://doi.org/10.1016/s0022-2836(03)00662-4
3. Zeng D, Debabov D, Hartsell TL, Cano RJ, Adams S, Schuyler JA, et al. Approved glycopeptide antibacterial drugs: mechanism of action and resistance. Cold Spring Harb Perspect Med. 2016;6(12):a026989. https://doi.org/10.1101/cshperspect.a026989
4. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983;5 Suppl 3:S407–11. https://doi.org/10.1093/clinids/5.supplement_3.s407
5. Schrezenmeier E, Minato Y, Dawadi S, Kordus SL, Sivanandam A, Aldrich CC, Baughn AD. Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole. Nat Commun. 2018;9(1):1003. https://doi.org/10.1038/s41467-018-03447-x
6. Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66. https://doi.org/10.1038/s41584-020-0372-x
Supplementary files
Review
For citations:
Safety of Antibacterial and Antiprotozoal Medicinal Products. Safety and Risk of Pharmacotherapy. 2022;10(2):196-199. (In Russ.) https://doi.org/10.30895/2312-7821-2022-10-2-196-199
Views: 800
Email this article 